DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 188 filers reported holding DENALI THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 2.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,964,813 | -31.4% | 289,133 | -1.9% | 0.04% | -27.1% |
| Q2 2023 | $8,699,282 | +24.6% | 294,791 | -2.7% | 0.05% | +17.1% |
| Q1 2023 | $6,980,000 | -23.2% | 302,961 | -7.9% | 0.04% | -26.8% |
| Q4 2022 | $9,092,000 | +16.0% | 329,084 | +28.8% | 0.06% | +9.8% |
| Q3 2022 | $7,840,000 | +1.0% | 255,460 | -3.1% | 0.05% | +4.1% |
| Q2 2022 | $7,760,000 | +18.3% | 263,704 | +29.4% | 0.05% | +44.1% |
| Q1 2022 | $6,557,000 | -24.0% | 203,850 | +6.4% | 0.03% | -10.5% |
| Q4 2021 | $8,627,000 | -29.5% | 191,516 | -21.0% | 0.04% | -30.9% |
| Q3 2021 | $12,236,000 | -46.4% | 242,545 | -16.7% | 0.06% | -43.9% |
| Q2 2021 | $22,834,000 | +28.4% | 291,103 | -8.4% | 0.10% | +24.1% |
| Q1 2021 | $17,778,000 | -29.1% | 317,862 | +6.2% | 0.08% | -44.0% |
| Q4 2020 | $25,059,000 | – | 299,186 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,705,039 | $343,645,000 | 25.68% |
| Casdin Capital, LLC | 1,500,000 | $66,900,000 | 1.89% |
| Flagship Pioneering Inc. | 2,619,968 | $116,851,000 | 1.81% |
| SECTORAL ASSET MANAGEMENT INC | 189,600 | $8,456,000 | 1.27% |
| Integral Health Asset Management, LLC | 100,000 | $4,460,000 | 1.23% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $239,479,000 | 0.86% |
| Goldstream Capital Management Ltd | 78,418 | $3,497,000 | 0.86% |
| Yiheng Capital Management, L.P. | 335,184 | $14,949,000 | 0.76% |
| GILDER GAGNON HOWE & CO LLC | 2,900,114 | $129,345,000 | 0.74% |
| Artal Group S.A. | 600,000 | $26,760,000 | 0.73% |